Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
7.16
-0.37 (-4.91%)
May 5, 2025, 4:00 PM EDT - Market closed
Daxor Revenue
In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%. Daxor had revenue of $47.96K in the half year ending December 31, 2024, a decrease of -50.25%.
Revenue (ttm)
$119.71K
Revenue Growth
-26.75%
P/S Ratio
297.46
Revenue / Employee
$3,236
Employees
37
Market Cap
35.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
DXR News
- 13 days ago - Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions - GlobeNewsWire
- 18 days ago - Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 - GlobeNewsWire
- 20 days ago - New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival - GlobeNewsWire
- 4 weeks ago - Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - GlobeNewsWire
- 5 weeks ago - Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewsWire
- 2 months ago - Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 - GlobeNewsWire
- 2 months ago - Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 - GlobeNewsWire